Pfizer Inc. (PFE)

NYQ – Цена в реальном времени. Валюта: USD

26.31

-0.31 (-1.16%)

При закрытии: Aug 12, 2026, 3:59 PM EDT

26.33

+0.02 (0.08%)

После закрытия: Aug 12, 2026, 6:52 PM EDT

12.08.2026

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.

12.08.2026

The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More

Investors love S&P 500 dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.

11.08.2026

Pfizer's Pipeline Could Change Everything

Pfizer is recovering from post-COVID and LOE-driven declines, with recent earnings beats and an attractive valuation supporting upside potential. PFE's Q2 2026 results showed 1% operational revenue growth and a 12% EPS beat, driven by solid non-COVID sales and a robust growth portfolio. Cost Realignment Program expansions are set to deliver $7.2B in net savings by 2026 and another $2.5B through 2029, enhancing future earnings.

11.08.2026

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Pfizer still relies somewhat heavily on Eliquis, a medicine that will lose patent exclusivity relatively soon. The company is working on several products that could help it overcome this challenge.

11.08.2026

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

AbbVie has solid financials, tons of free cash flow, and it has tripled its dividend in the past decade. Pfizer's massive 6.4% yield may not be as risky as investors think, and the company has been investing in its future growth.

11.08.2026

Stop Chasing Yield: 2 Dividend Stocks I Want Now

Carlisle Companies offers a 1.3% yield, 50 years of dividend growth, and robust buybacks, supported by a low payout ratio and Vision 2030 targets. CSL's business is resilient due to commercial remodeling demand, with management targeting $40 EPS by 2030 and a potential doubling of the stock in 5–7 years. Pfizer yields 6.4% but faces near-term EPS declines. Dividend growth is paused until at least 2028 as the company rebuilds its drug pipeline.

10.08.2026

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Impairment charges crippled Pfizer's recent earnings. The company's free cash flow, however, remains fairly strong.

Видео

No Data

There is no data to display

Пресс-релизы

04.08.2026

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter, delivering on our financial commitments and adva.

Pfizer Inc. (PFE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Pfizer Inc. (PFE)

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More

Pfizer's Pipeline Could Change Everything

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

Stop Chasing Yield: 2 Dividend Stocks I Want Now

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Видео

No Data

Пресс-релизы

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More

Pfizer's Pipeline Could Change Everything

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

Stop Chasing Yield: 2 Dividend Stocks I Want Now

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Видео

No Data

Пресс-релизы

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Search stocks

Pfizer Inc. (PFE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Pfizer Inc. (PFE)

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More

Pfizer's Pipeline Could Change Everything

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

Stop Chasing Yield: 2 Dividend Stocks I Want Now

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Видео

No Data

Пресс-релизы

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More

Pfizer's Pipeline Could Change Everything

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

Stop Chasing Yield: 2 Dividend Stocks I Want Now

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Видео

No Data

Пресс-релизы

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance